Overspending on Antiemetic Drugs Not Decreasing, Despite ASCO Guidelines

Share this content:
Financial performance incentives may be useful for reducing overspending on antiemetic drugs for patients undergoing chemotherapy.
Financial performance incentives may be useful for reducing overspending on antiemetic drugs for patients undergoing chemotherapy.

Financial performance incentives may be useful for reducing overspending on antiemetic drugs for patients undergoing chemotherapy, according to an article published in JAMA Oncology.1

Antiemetic drugs help prevent nausea and vomiting among patients undergoing chemotherapy. In 2013, the American Society for Clinical Oncology (ASCO) recommended that oncologists not overuse these drugs, which can be very expensive. For the present study, researchers evaluated whether physicians are adhering to ASCO's guidelines.

For almost a quarter of the 678,220 patients included in the study, antiemetic drugs were overused (defined by comparing drug use to risk of nausea from a chemotherapy regimen). Overuse of antiemetic drugs, overall, has not changed drastically since the 2013 ASCO guidelines were published.

RELATED: Standard Antiemetic Therapy Efficacious During TC Chemotherapy

The authors conclude that voluntary reduction in the overuse of antiemetic drugs is not sufficient for uniform practice of the 2013 ASCO guidelines. Other incentives may be necessary to reduce this overuse, in an effort to lower the ever-increasing cost of cancer care in the United States.

Study limitations, such as inability to accurately measure all chemotherapy doses, may have influenced these results.

Reference

  1. Encinosa W, Davidoff AJ. Changes in antiemetic overuse in response to choosing wisely recommendations. JAMA Oncol. 2016 Sep 15. doi: 10.1001/jamaoncol.2016.2530 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters